Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Erdheim-Chester Histiocytosis Presenting as Ankle Disease

Calvo-Galindo, Roberto MD; Moreno-García, Marina Soledad MD; del Río-Martínez, Pilar MD, PhD; Casorrán-Berges, Marta MD; Valero-Tena, Esther MD; Aznar-Villacampa, Emilia MD, PhD; Delgado-Beltrán, Concepción MD, PhD

JCR: Journal of Clinical Rheumatology: March 2016 - Volume 22 - Issue 2 - p 99–101
doi: 10.1097/RHU.0000000000000369
Letters to the Editor

Rheumatology Department Hospital Clínico Universitario “Lozano Blesa” Zaragoza, Spain

The authors declare no conflict of interest.

All the products included in the article (IFN-α, peg-IFN-α, vemurafenib, anakinra, infliximab, tocilizumab) are not approved by FDA for Erdheim-Chester disease and are still under investigational use.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.